title: Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats.
abstract: A previous study in subtotally nephrectomized (SNX) rats suggested beneficial effects of the calcimimetic R-568 beyond the control of mineral metabolism. This study analyzed potential blood pressure (BP)-lowering effects of R-568. Male Sprague-Dawley rats received two-stage subtotal nephrectomy or sham operation. Telemetry devices were inserted into the abdominal aorta, and BP was measured every 5 min. R-568 (20 mg/kg per d) or solvent was infused for 4 wk followed by once-daily subcutaneous injections for 2 wk. Total body sodium was measured by neutron activation analysis. The uremia-induced increase of mean arterial pressure from baseline to day 42 in SNX solvent rats (103+/-5 to 128+/-14 mmHg, P=0.006) was attenuated by R-568 (104+/-5 to 111+/-8 mmHg; P<0.0001 for difference of slopes). The circadian rhythm was abrogated in SNX rats and not restored by R-568. In sham-operated rats, R-568 had only a minor transient antihypertensive effect. R-568 injection induced a transient rise of mean arterial pressure by 23+/-4 and 26+/-10 mmHg in sham and SNX rats but only by 9+/-3 and 10+/-5 mmHg in solvent-treated rats (P<0.01 versus baseline and solvent versus R-568). Plasma angiotensin-converting enzyme activity and aldosterone levels were similar; food intake and physical activity did not differ throughout the study. In healthy rats, total body sodium was higher after 14 d of R-568 compared with solvent infusion (37.1+/-4 versus 32.5+/-1.4 mmol/kg; P=0.01). The calcimimetic R-568 causes an initial BP increase in sham-operated and uremic rats, which in uremic rats is followed by a marked and sustained antihypertensive effect.
authors.affiliation: Department of Pediatrics, University of Heidelberg, Germany.
authors.forename: Tobias
authors.initials: T
authors.lastname: Odenwald
authors.forename: Kumiko
authors.initials: K
authors.lastname: Nakagawa
authors.forename: Charlotte
authors.initials: C
authors.lastname: Hadtstein
authors.forename: Frank
authors.initials: F
authors.lastname: Roesch
authors.forename: Peter
authors.initials: P
authors.lastname: Gohlke
authors.forename: Eberhard
authors.initials: E
authors.lastname: Ritz
authors.forename: Franz
authors.initials: F
authors.lastname: Schaefer
authors.forename: Claus Peter
authors.initials: CP
authors.lastname: Schmitt
mesh_terms: D000208:Acute Disease; D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D001795:Blood Pressure Determination; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D007022:Hypotension / Q000209:etiology* / Q000503:physiopathology; D007279:Injections, Subcutaneous; D008297:Male; D009392:Nephrectomy; D010627:Phenethylamines; D011336:Probability; D011437:Propylamines; D051381:Rats; D017207:Rats, Sprague-Dawley; D012084:Renin-Angiotensin System / Q000187:drug effects; D012680:Sensitivity and Specificity; D012964:Sodium / Q000378:metabolism*; D013997:Time Factors; D014511:Uremia / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000814:Aniline Compounds; C107873:N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine; D010627:Phenethylamines; D011437:Propylamines; D012964:Sodium